BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36530690)

  • 1. Cervical cancer elimination in Italy: Current scenario and future endeavors for a value based prevention.
    Calabrò GE; Riccardi MT; D'Ambrosio F; Castagna C; Sapienza M; Millevolte R; Pellacchia A; Ricciardi R; de Vincenzo RP; de Waure C
    Front Public Health; 2022; 10():1010237. PubMed ID: 36530690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
    Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
    Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control.
    Hall MT; Smith MA; Simms KT; Barnabas R; Murray JM; Canfell K
    Int J Cancer; 2021 Jul; 149(2):297-306. PubMed ID: 33634857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
    Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
    Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
    Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
    Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
    Canfell K; Kim JJ; Brisson M; Keane A; Simms KT; Caruana M; Burger EA; Martin D; Nguyen DTN; Bénard É; Sy S; Regan C; Drolet M; Gingras G; Laprise JF; Torode J; Smith MA; Fidarova E; Trapani D; Bray F; Ilbawi A; Broutet N; Hutubessy R
    Lancet; 2020 Feb; 395(10224):591-603. PubMed ID: 32007142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
    Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
    Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
    Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid elimination of cervical cancer while maintaining the harms and benefits ratio of cervical cancer screening: a modelling study.
    Jansen EEL; de Kok IMCM; Kaljouw S; Demirel E; de Koning HJ; Hontelez JAC
    BMC Med; 2022 Nov; 20(1):433. PubMed ID: 36352410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Consensus Project: Participation in cervical cancer screening by the first cohorts of girls offered HPV vaccination at age 15-16 years in Italy.
    Visioli CB; Giorgi Rossi P; Armaroli P; Iossa A; Rizzolo R; Bonelli LA; Venturino E; Carozzi FM; Bisanzi S; De Marco L; Giordano L; Camussi E; Del Mistro A; Zappa M
    J Med Screen; 2023 Sep; 30(3):142-149. PubMed ID: 36999190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The European response to the WHO call to eliminate cervical cancer as a public health problem.
    Arbyn M; Gultekin M; Morice P; Nieminen P; Cruickshank M; Poortmans P; Kelly D; Poljak M; Bergeron C; Ritchie D; Schmidt D; Kyrgiou M; Van den Bruel A; Bruni L; Basu P; Bray F; Weiderpass E
    Int J Cancer; 2021 Jan; 148(2):277-284. PubMed ID: 32638362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis.
    Choi HCW; Leung K; Chan KKL; Bai Y; Jit M; Wu JT
    BMC Med; 2023 Feb; 21(1):48. PubMed ID: 36765349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping HPV Vaccination and Cervical Cancer Screening Practice in the Pacific Region-Strengthening National and Regional Cervical Cancer Prevention.
    Obel J; McKenzie J; Buenconsejo-Lum LE; Durand AM; Ekeroma A; Souares Y; Hoy D; Baravilala W; Garland SM; Kjaer SK; Roth A
    Asian Pac J Cancer Prev; 2015; 16(8):3435-42. PubMed ID: 25921158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Qualitative Study of Parental Knowledge and Perceptions of Human Papillomavirus and Cervical Cancer Prevention in Rural Central Java, Indonesia: Understanding Community Readiness for Prevention Interventions.
    Spagnoletti BRM; Bennett LR; Wahdi AE; Wilopo SA; Keenan CA
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2429-2434. PubMed ID: 31450917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: A model-based analysis.
    Portnoy A; Pedersen K; Trogstad L; Hansen BT; Feiring B; Laake I; Smith MA; Sy S; Nygård M; Kim JJ; Burger EA
    Prev Med; 2021 Mar; 144():106276. PubMed ID: 33678239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Papillomavirus Vaccination in South Africa: Programmatic Challenges and Opportunities for Integration With Other Adolescent Health Services?
    Amponsah-Dacosta E; Blose N; Nkwinika VV; Chepkurui V
    Front Public Health; 2022; 10():799984. PubMed ID: 35174123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
    Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
    Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.